Search

Displaying results 2341 - 2350 of 10000 in total
  1. Drug

    Tagraxofusp

    go.drugbank.com/drugs/DB14731
    ApprovedInvestigational

    [A253762] It was also approved by the European Commission on January 7, 2021.[L43712] … a myeloid malignancy in the dendritic cell lineage.

  2. Drug

    Recombinant stabilized RSV B prefusion F antigen

    go.drugbank.com/drugs/DB18714
    ApprovedInvestigational

    [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of … [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023.

  3. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    Its use has also proven successful in the treatment of HCV in patients co-infected with HIV [A19627]. … In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend ledipasvir as a first line

    Mixtures: HARVONI 90 MG/400 MG FILM KAPLI TABLET, 84 ADET, HARVONI 90 MG/400 MG FILM KAPLI TABLET, 28 ADET
  4. Drug

    Chlorobutanol

    go.drugbank.com/drugs/DB11386
    ApprovedVet approvedWithdrawn

    Chlorobutanol, or chlorbutol, is an alcohol-based preservative with no surfactant activity [A32746]. … Similar in nature to chloral hydrate, it is formed by the simple nucleophilic addition of chloroform and acetone.

    Mixtures: DİŞİNOL 2 G + 0,5 G + 3,5 G/10 ML ÇÖZELTİ, NOSTIL 75 MG/60MG/35MG BURUN SPREYİ, ÇÖZELTİ, 15 MLCategories: Compounds used in a research, industrial, or household setting
  5. Drug

    Streptococcus pneumoniae type 5 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10323
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR, Prevnar 20
  6. Drug

    Streptococcus pneumoniae type 23f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10340
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR, Prevnar 20
  7. Drug

    Tosedostat

    go.drugbank.com/drugs/DB11781
    Investigational

    Tosedostat is an inhibitor of the M1 family of aminopeptidases, in particular PuSA, and LTA4 hydrolase. … It has demonstrated anti-tumour activity in a number of models of cancer, both as a single agent and in synergy with cytotoxic agents such as carboplatin and paclitaxel.

  8. Target

    Integrase, catalytic core

    go.drugbank.com/bio_entities/BE0003386
    TargetNitrosomonas europaea (strain ATCC 19718 / NBRC 14298)

    Polypeptides: Integrase, catalytic core
  9. Target

    Neurocan core protein

    go.drugbank.com/bio_entities/BE0004512
    TargetHumans

    May modulate neuronal adhesion and neurite growth during development by binding to neural cell adhesion molecules (NG-CAM and N-CAM). Chondroitin sulfate proteoglycan; binds to hyaluronic acid

    Polypeptides: Neurocan core protein
  10. Target

    Versican core protein

    go.drugbank.com/bio_entities/BE0004606
    TargetHumans

    May play a role in intercellular signaling and in connecting cells with the extracellular matrix. May take part in the regulation of cell motility, growth and differentiation. Binds hyaluronic acid

    Polypeptides: Versican core proteinSynonyms: Chondroitin sulfate proteoglycan core protein 2